ALA just got 5m in cash and its iNKT - platform gets developed by IMU to get an IND approval. IMU got about 185m and maybe soon more than 200m in cash and got several platforms in clinical trials.
At ALA hardly any cash and just one non - clinical platform sees its sp almost double in a week while IMU gets hammered. Something isn't right. Either cash and IP counts or not. If ALA is a guide to go buy then IMU should really throw its cash and IP away to increase the sp. Sometimes the market makes no sense at all unless ALA gets pumped for a CR. But if that's the case then how could they get a premium for almost nothing while Hopper is discounting IMU for probably the cure for solid cancer and tells us there is no money out there.
GLTA
The CF33, Vaxinia and Oncarlytics Deal, page-815
-
- There are more pages in this discussion • 273 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.3¢ |
Change
0.001(0.96%) |
Mkt cap ! $385.8M | |||
| Open | High | Low | Value | Volume |
| 5.3¢ | 5.3¢ | 5.2¢ | $69.62K | 1.320M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 43 | 2128578 | 5.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.3¢ | 964663 | 16 |
View Market Depth
| Last trade - 13.30pm 19/08/2024 (20 minute delay) ? |
| IMU (ASX) Chart |